April 23rd 2024
Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.
Semaglutide Cuts Cardiovascular Risk by 20% in Adults with Obesity, CVD and Without Diabetes
November 13th 2023AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.